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The death last month of Superman
actor Christopher Reeve, aged 52,
attracted enormous media
coverage. While his fame originally
lay with his acting, his efforts in
support of stem-cell research
since the horse-riding accident in
1995 that left him quadraplegic
have deeply affected friends and
commentators.
Reeve became a vocal advocate
for this research field. In stem
cells, he saw a powerful tool being
hampered by US policy, a tool that
promised potential therapies, not
just to heal himself, but to treat a
host of medical conditions in
others.
The Los Angeles Times
highlighted his role in the
campaign last month of the (then)
presidential candidate Democrat
John Kerry, reporting Kerry as
saying in one of the televised
presidential debates “that he
believed embryonic stem cell
research should be expanded,
saying it would be the best way to
give Reeve and others like him the
chance for a better life.”
The New York Times reported
comments by Sean Tipton, a
spokesperson for the coalition for
the Advancement of Medical
Research, an umbrella group of
organisations dedicated to the
promotion of stem-cell studies.
“He has been such an inspiration
to us personally that those of us
involved in stem cell advocacy are
going to have to figure out how we
are going to continue without his
leadership, and without his very
visible presence.”
The paper also reported the
comment from Larry Soler, a
spokesperson for the Juvenile
Diabetes Research Foundation,
which does not endorse political
candidates, who said that Reeve’s
death was “an important reminder
to us that time is of the essence
with this research.”
And Reeve made a difference.
He campaigned in Congress. He
was the public figure that brought
the stem-cell debate to the public.
“He was the human voice that
changed attitudes,” says Colin
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Medical man: The global media has widely reported the death last month  of Superman actor, Christopher Reeve, who has been
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The death last month of actor Christopher Reeve led to an outpouring
of media tributes for his role as Superman but also to widespread
coverage of his commited support for stem-cell research as a route to
potential new treatments. Nigel Williams reports.
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“It’s one thing for scientists to say
‘we know we can do this’, but
Christopher Reeve put all this into
real-life perspective.”
The Washington Post said that
the actor believed that such
innovative medical procedures
would allow him and millions of
others with spinal cord injuries
someday to walk again. “He was
an outspoken critic of President
Bush’s 2001 decision to limit
federal funding to existing cell
lines.”
“Perhaps it is my job to offend
some scientists,” quotes the
paper, reporting Reeve talking to
the Lasker Foundation last year
after receiving the group’s annual
award for public service. “I’m not
asking them to be reckless or
unprofessional, but I do want to
reinforce a sense of urgency.”
Reeve came to the stem-cell
debate when the US was
considering outlawing
therapeutic cloning, a technique
where stem cells are harvested
from surplus fertilized eggs in
fertility clinics. Such embryonic
stem cells, it is thought, can be
turned into any of the hundreds
of cell types in the body. To its
supporters, few medical
technologies have held more
promise, as such stem cells
could potentially be used to
replace damaged and diseased
cells anywhere in the body. To its
critics — and in Washington, that
meant many Republicans and the
religious right — the creation of
embryos is morally repugnant.
Reeve saw the resistance as a
challenge. With an eye on the
electorate, the Bush administration
imposed strict controls on
therapeutic cloning, declaring that,
while private institutions could do
whatever they wanted, federal
funds could only be used to
research stem cells created before
2001. Without the full weight of
federal funding behind it, Reeve
and many scientists felt stem cell
research had been scuppered. He
set up the Christopher Reeve
Paralysis Foundation to fund some
of the best research into therapies
for paralysis, but the $15 million a
year the foundation dedicated to
research was just a fraction of
what the US National Institutes of
Health could have paid for, if the
Bush administration had allowed it.
Despite the restrictions in the
US, which presidential candidate
John Kerry has vowed to lift
should the US electorate give him
the chance, stem-cell research
continues at a developing pace.
Last year, the California-based
company Geron announced they
had used an injection of human
embryonic stem cells to restore
some function to rats which had
had their spinal cords cut. The
work, though promising, is still a
lab study. In the real world,
fractures are messy and when
nerves are damaged in the spine,
the injury site is quickly mobbed
with cells that make nerve repair
extremely difficult.
In other companies and
universities, stem cells are also
being put through their paces to
see if they can help conditions as
disparate as Parkinson’s,
Alzheimers, diabetes and motor
neuron disease. Other are using
stem cells to correct irregular
heart beats and salvage damaged
retinas.
The Boston Globe reported
shortly after Reeve’s death that
two separate teams of Harvard
researchers are seeking to
produce cloned embryos for
disease research, and that one
had officially applied for
permission form the university’s
ethical review board. Both teams
are part of the recently formed
Harvard Stem Cell Institute, set up
by the university earlier this year.
“This is exactly the kind of work
we envisioned for the Harvard
Stem Cell Institute,” says Doug
Melton, the senior researcher on
one of the teams.
In Britain, one of just a handful
of countries to have firm
legislation allowing therapeutic
cloning to produce stem cells,
only one licence has so far been
granted for such research. Based
at Newcastle University, Miodrag
Stojkovich and Alison Murdoch of
the Newcastle Fertility Centre
hope to produce stem cells to
study diabetes and Reeve’s
contribution to helping the public
understand the merits of stem-
cell research is not lost on them.
And earlier this autumn, Ian
Wilmut, the scientist who became
a public name through his work
creating Dolly the sheep, applied
for a licence to clone embryos to
make stem cells, this time to to
treat motor neuron disease. If
their application gets the green
light from the Human Fertility and
Embryology Authority, the body
that controls such research in the
UK, the team hope to begin work
next spring.
And a new group at University
College London led by Geoffrey
Geoff Raisman hopes to use
adult-derived stem cells to treat
spinal-cord injury patients within
the next few years. His team
discovered that there were some
cells within the nervous system, in
the nasal cavity and involved with
the sense of smell, which were in
a continual state of growth
throughout life. Raisman, formerly
at the National Institute for
Medical Research in London,
found that these cells had a
remarkable capacity to integrate
into damaged pathways in the
spinal cords of rats.
Within the stem cell community,
arguments still occur over
whether funding should be
skewed in favour of more versatile
embryonic stem cells or the less
ethically problematic adult stem
cells. These provoke less
controversy because they can be
be extracted from people who are
able to give consent. Bone
marrow has long been known as a
rich source of adult stem cells,
and they are also at the base of
hair follicles, where they help
stimulate hair growth. But
researchers believe adult stem
cells have a downside — they
cannot be transformed into any
kind of cell. Their role in the body
has already, at least in part, been
determined. More versatile may
be stem cells taken from the
blood of umbilical cords, though
again, these have limits on what
they can develop into.
Whatever the future focus of
stem-cell research, Reeve’s very
public and outspoken stance on
the value of stem-cell research is
likely to have a significant impact
on research priorities both in the
US and other countries too where
his acting has had such an impact
on public perception.
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